Diagnostics and wellness testing platform Healthians turned profitable in FY26, marking a significant financial milestone after operating near breakeven in the previous fiscal year. The company’s revenue growth outpaced its increase in expenses, helping it move from a loss to profitability.
Healthians reported revenue from operations of ₹357 crore in FY26, up 35.7% from ₹263 crore in FY25. Including ₹5 crore in interest income, total revenue reached ₹362 crore during the year.
Diagnostics remained the company’s core business, contributing approximately 99% of operating revenue, or ₹353 crore. Healthians offers at-home diagnostic services across more than 250 cities and claims to have conducted over 10 crore tests since its inception.
The company’s expenses continued to rise as it scaled operations, although at a slower pace than revenue. Total expenditure increased 32.4% to ₹364 crore in FY26. Employee benefits were the largest expense, rising 28% to ₹134 crore and accounting for 36.8% of total expenditure. Material costs stood at ₹109 crore, while marketing expenses declined to ₹44 crore.
The improved operating leverage helped Healthians report a net profit of ₹5.4 crore in FY26, compared with a loss of ₹4.77 crore in FY25. Its EBITDA margin improved to 2.20%, signalling progress in operational efficiency, although the company still spent ₹1.02 to generate every ₹1 of operating revenue.
Healthians ended FY26 with current assets worth ₹112.5 crore but continues to carry accumulated losses of ₹976 crore, highlighting the distance still to be covered despite its first profitable year.
The financial turnaround also comes during a leadership transition. Founder Deepak Sahni stepped away from formal executive responsibilities in January 2026 after building the company over the past decade.
Backed by investors including WestBridge, BEENEXT, DG Ventures and YouWeCan, Healthians has raised around $75 million to date. It operates in an increasingly competitive diagnostics market alongside players such as Orange Health, Redcliffe Labs and Dr Lal PathLabs.
The next phase of growth will likely depend on Healthians’ ability to balance expansion with sustainable margins. As competition drives greater adoption of preventive diagnostics, the opportunity extends beyond routine testing. Technology-led approaches, including AI and newer diagnostic models, could help platforms create more meaningful insights around future health risks and actionable interventions.
For Healthians, FY26 represents an important inflection point: the business has demonstrated that growth and profitability can begin moving together. The challenge now is turning this financial turnaround into sustained operating strength in India’s evolving diagnostics and preventive healthcare market.
Source: Based on reporting by Entrackr, with additional editorial adaptation and analysis.
